Product name:  Elacestrant

Cas NO.:722533-56-4


M.W.:  458.63

Capacity:  1200KG/M

Usage:  Cancer/Tumor


■ Description

Cas 722533-56-4 name Elacestrant is used to treat certain types of hormone receptor-positive breast cancer such as breast cancer that depends on hormones such as estrogen to grow. It is mainly for adults who have had disease progression following treatment with at least one other hormone therapies

elacestrant powder api.png

 On January27, 2023, the  (FDA)  Food and Drug Administration approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, which is a great news.

Million pharmaceutical focuses on new drug api development and becomes only elacestrant stock manufacture. We also complete the full tech pack of elacestrant api and intermediates.

■ Message